The centre led the WOSCOP study (New England Journal of Medicine 1995; 333:1301-7) which found that treatment with Pravastatin significantly reduced the risk of myocardial infarction and the risk of death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolaemia and no history of myocardial infarction.